Valeria Santini

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · Journal of Clinical Oncology · 2009 · 951 citations · Full text

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Elsa Bernard, Heinz Tuechler, Peter L. Greenberg et al. · NEJM Evidence · 2022 · 746 citations · Full text

Mixed-phenotype Acute Leukemia, Prognosis, Genetic Epidemiology +20

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian et al. · Nature Medicine · 2020 · 606 citations · Full text

Hematological Malignancy, Chromatin, Genome Stability +11

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 519 citations · Full text